An inexpensive and readily accessible anti-inflammatory drug reduces the risk of a potentially dangerous complication in patients starting treatment for both TB and HIV.
The international team which carried out the clinical trial in South Africa included scientists from the Crick. Their results provide the first evidence for an effective strategy to prevent this common complication, which would be an important step in South Africa and other parts of sub-Saharan Africa dealing with the dual epidemics of HIV and TB.
In sub-Saharan Africa, people with HIV frequently also develop TB. People arriving at clinics with TB symptoms are often found to have both HIV infection and active TB disease.